Equities Analysts Set Expectations for CLRB Q1 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Equities researchers at Brookline Capital Markets issued their Q1 2027 earnings per share estimates for Cellectar Biosciences in a research report issued to clients and investors on Sunday, July 12th. Brookline Capital Markets analyst K. Dolliver forecasts that the biopharmaceutical company will earn ($0.50) per share for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.34) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.34) EPS.

Several other brokerages have also issued reports on CLRB. Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Monday, April 20th. LADENBURG THALM/SH SH started coverage on shares of Cellectar Biosciences in a research note on Friday, May 15th. They set a “buy” rating for the company. Wall Street Zen upgraded Cellectar Biosciences to a “hold” rating in a report on Saturday, June 20th. Finally, Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Cellectar Biosciences in a report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Cellectar Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Cellectar Biosciences Stock Performance

Shares of NASDAQ:CLRB opened at $2.63 on Tuesday. The firm’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $2.99. Cellectar Biosciences has a one year low of $2.20 and a one year high of $6.52. The firm has a market cap of $21.01 million, a PE ratio of -0.39 and a beta of 0.55.

Cellectar Biosciences (NASDAQ:CLRB) last released its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating the consensus estimate of ($1.88) by $0.55.

Hedge Funds Weigh In On Cellectar Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Cellectar Biosciences during the fourth quarter worth about $36,000. DRW Securities LLC lifted its position in shares of Cellectar Biosciences by 114.2% in the fourth quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 24,089 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Cellectar Biosciences by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 3,744 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Cellectar Biosciences by 135.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 14,567 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences during the third quarter worth approximately $104,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical?stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope?labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B?cell malignancies, including multiple myeloma and non?Hodgkin lymphoma.